Ipratropium Bromide: Overview and Core Content

Ipratropium bromide is an anticholinergic drug mainly used to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. It blocks M3 receptors on bronchial smooth muscle, reducing airway spasm and mucus secretion, thereby improving patients' respiratory function. This article will start fromPharmacological effects, clinical applications, usage, precautionsandManufacturerFive aspects are developed, focusing on analyzing its efficacy and safety, with authoritative data support.

Pharmacological effects and mechanisms

Ipratropium bromide selectively inhibits the M3 receptor of bronchial smooth muscle, reducing intracellular calcium ion concentration, causing muscle relaxation and airway dilation. Compared with β2 receptor agonists (such as albuterol), its onset of action is slightly slower (about 15-30 minutes), but its duration of action is longer (4-6 hours), making it suitable as maintenance treatment for COPD patients. Studies have shown that its combination with β2 receptor agonists can significantly improve the efficacy (such as an increase in FEV1 improvement rate of 20%-30%).

Clinical applications and indications

Ipratropium bromide is widely usedCOPD stable phaseandAsthma adjuvant treatment, especially suitable for patients who are intolerant to beta2 receptor agonists. The Global Initiative for Asthma (GINA) guidelines recommend it as a second-line drug. Clinical data shows that long-term use can reduce the frequency of acute attacks by about 25% (Source:New England Journal of Medicine). It should be noted that this drug is not suitable for the rescue of acute bronchospasm.

How to use and precautions

Common dosage forms areinhalation solutionorAerosol, needs to be administered via a nebulizer or metered dose inhalation device. The recommended dose for adults is 20-40 μg 3-4 times daily. Common side effects include dry mouth and headache, with an incidence rate of less than 10% (

adverse reactions	incidence
dry mouth	8%
headache	5%

). Patients with glaucoma and prostatic hypertrophy should use it with caution and avoid combining it with other anticholinergic drugs.

Summary and production information

Ipratropium bromide is one of the cornerstone drugs in COPD management, with both safety and efficacy. At present, major domestic manufacturers includeBoehringer Ingelheim(Trade name: Ai Quan Le),It's sunnyWait. Patients need to follow the doctor's instructions and use it regularly, and have their lung function evaluated regularly. Its clinical value has been confirmed by many studies, such asTORCH researchShown that long-term use can delay the decline of lung function (source:"The Lancet").

Citing sources

1. Global Initiative for Asthma (GINA) 2023 Guidelines
2. "New England Journal of Medicine": Randomized controlled trial of ipratropium bromide in the treatment of COPD
3. Boehringer Ingelheim’s official website: Atolen Product Manual
4. "The Lancet": Long-term follow-up data of the TORCH study